Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 2582745, 10 pages
https://doi.org/10.1155/2017/2582745
Research Article

Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells

1Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia
2School of Pharmacy, Griffith University, Gold Coast, QLD, Australia
3Quality Use of Medicines Network, Gold Coast, QLD 4222, Australia

Correspondence should be addressed to S. Anoopkumar-Dukie; ua.ude.htiffirg@eikud.s

Received 9 October 2016; Revised 15 February 2017; Accepted 13 March 2017; Published 4 May 2017

Academic Editor: Elaine Hatanaka

Copyright © 2017 A. J. McFarland et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Antonopoulos, M. Margaritis, R. Lee, K. Channon, and C. Antoniades, “Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials,” Current Pharmaceutical Design, vol. 18, no. 11, pp. 1519–1530, 2012. View at Publisher · View at Google Scholar
  2. C. Antoniades, C. Bakogiannis, P. Leeson et al., “Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling,” Circulation, vol. 124, no. 3, pp. 335–345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Jarvisalo, J. O. Toikka, T. Vasankari et al., “HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease,” Atherosclerosis, vol. 147, no. 2, pp. 237–242, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. S. E. Nissen, E. M. Tuzcu, P. Schoenhagen et al., “Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial,” Jama, vol. 291, no. 9, pp. 1071–1080, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Alfon, T. Royo, X. Garcia-Moll, and L. Badimon, “Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 7, pp. 1812–7, 1999. View at Publisher · View at Google Scholar
  6. G. Huhle, C. Abletshauser, N. Mayer, G. Weidinger, J. Harenberg, and D. L. Heene, “Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor,” Thrombosis Research, vol. 95, no. 5, pp. 229–234, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. McFarland, S. Anoopkumar-Dukie, D. S. Arora et al., “Molecular mechanisms underlying the effects of statins in the central nervous system,” International Journal of Molecular Sciences, vol. 15, no. 11, pp. 20607–20637, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. P. A. Reis, V. Estato, T. I. da Silva et al., “Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria,” PLoS Pathogens, vol. 8, no. 12, e1003099, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Albert, E. Danielson, N. Rifai, P. M. Ridker, and PRINCE Investigators, “Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study,” Jama, vol. 286, no. 1, pp. 64–70, 2001. View at Publisher · View at Google Scholar
  10. E. Ascer, M. C. Bertolami, M. L. Venturinelli et al., “Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients,” Atherosclerosis, vol. 177, no. 1, pp. 161–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. van de Ree, M. V. Huisman, H. M. Princen, A. E. Meinders, C. Kluft, and DALI-Study Group, “Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus,” Atherosclerosis, vol. 166, no. 1, pp. 129–135, 2003. View at Google Scholar
  12. M. Massaro, A. Zampolli, E. Scoditti et al., “Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability,” Cardiovascular Research, vol. 86, no. 2, pp. 311–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. N. A. Turner, D. J. O’Regan, S. G. Ball, and K. E. Porter, “Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels,” The FASEB Journal, vol. 19, no. 7, pp. 804–806, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ortego, C. Bustos, M. A. Hernández-Presa et al., “Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells,” Atherosclerosis, vol. 147, no. 2, pp. 253–261, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Umeji, S. Umemoto, S. Itoh et al., “Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 291, no. 5, pp. H2522–H2532, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Haendeler, J. Hoffmann, A. M. Zeiher, and S. Dimmeler, “Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins,” Circulation, vol. 110, no. 7, pp. 856–861, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Amarenco and A. M. Tonkin, “Statins for stroke prevention: disappointment and hope,” Circulation, vol. 109, supplement 1, no. 23, pp. III-44–III-49, 2004. View at Google Scholar
  18. Council, T.S, “Statins after ischemic stroke and transient ischemic attack: an advisory statement from the stroke council, American Heart Association and American Stroke Association,” Stroke, vol. 35, no. 4, p. 1023, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. S. E. Nissen, E. M. Tuzcu, P. Schoenhagen et al., “Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease,” New England Journal of Medicine, vol. 352, no. 1, pp. 29–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Vale, A. J. Nordmann, G. G. Schwartz et al., “Statins for acute coronary syndrome,” Cochrane Database of Systematic Reviews, vol. 9, no. 9, article Cd006870, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. L. R. Wagstaff, M. W. Mitton, B. M. Arvik, and P. M. Doraiswamy, “Statin-associated memory loss: analysis of 60 case reports and review of the literature,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 23, no. 7, pp. 871–880, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. K. J. Swiger, R. J. Manalac, R. S. Blumenthal, M. J. Blaha, and S. S. Martin, “Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects,” Mayo Clinic Proceedings, vol. 88, no. 11, pp. 1213–1221, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Pihl-Jensen, A. Tsakiri, and J. L. Frederiksen, “Statin treatment in multiple sclerosis: a systematic review and meta-analysis,” CNS Drugs, vol. 29, no. 4, pp. 277–291, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Collins, C. Reith, J. Emberson et al., “Interpretation of the evidence for the efficacy and safety of statin therapy,” The Lancet, vol. 388, no. 10059, pp. 2532–2561, 2016. View at Publisher · View at Google Scholar
  25. R. M. Clarke, F. O’Connell, A. Lyons, and M. A. Lynch, “The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-β 1–42 in the rat hippocampus in vivo,” Neuropharmacology, vol. 52, no. 1, pp. 136–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Kata, I. Földesi, L. Z. Feher, L. Hackler Jr, L. G. Puskas, and K. Gulya, “Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells,” Neuroscience, vol. 314, pp. 47–63, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Cordle and G. Landreth, “3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses,” The Journal of Neuroscience, vol. 25, no. 2, pp. 299–307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Barone, G. Cenini, F. Di Domenico et al., “Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action,” Pharmacological Research, vol. 63, no. 3, pp. 172–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. T. C. Piermartiri, C. P. Figueiredo, D. Rial et al., “Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β 1–40 administration in mice: evidence for dissociation between cognitive deficits and neuronal damage,” Experimental Neurology, vol. 226, no. 2, pp. 274–284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. X.-K. Tong, N. Nicolakakis, P. Fernandes et al., “Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice,” Neurobiology of Disease, vol. 35, no. 3, pp. 406–414, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Q. Xu, L. Long, J. Q. Yan et al., “Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K/AKT/caspase 3 pathway and anti-inflammatory responses,” CNS Neuroscience & Therapeutics, vol. 19, no. 3, pp. 170–177, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Churchward and K. G. Todd, “Statin treatment affects cytokine release and phagocytic activity in primary cultured microglia through two separable mechanisms,” Molecular Brain, vol. 7, no. 1, pp. 1–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Schwende, E. Fitzke, P. Ambs, and P. Dieter, “Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3,” Journal of Leukocyte Biology, vol. 59, no. 4, pp. 555–561, 1996. View at Google Scholar
  34. M. Daigneault, J. A. Preston, H. M. Marriott, M. K. Whyte, and D. H. Dockrell, “The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages,” PloS One, vol. 5, no. 1, article e8668, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Takashiba, T. E. Van Dyke, S. Amar, Y. Murayama, A. W. Soskolne, and L. Shapira, “Differentiation of monocytes to macrophages primes cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor κB,” Infection and Immunity, vol. 67, no. 11, pp. 5573–5578, 1999. View at Google Scholar
  36. E. Park, H. S. Jung, H. I. Yang, M. C. Yoo, C. Kim, and K. S. Kim, “Optimized THP-1 differentiation is required for the detection of responses to weak stimuli,” Inflammation Research, vol. 56, no. 1, pp. 45–50, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Qin, X. Wu, M. L. Block et al., “Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration,” Glia, vol. 55, no. 5, pp. 453–462, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Ha, E. Moon, P. Lee, J. H. Ryu, M. S. Oh, and S. Y. Kim, “Acacetin attenuates neuroinflammation via regulation the response to LPS stimuli in vitro and in vivo,” Neurochemical Research, vol. 37, no. 7, pp. 1560–1567, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. D. A. Gayle, Z. Ling, C. Tong, T. Landers, J. W. Lipton, and P. M. Carvey, “Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide,” Brain Research. Developmental Brain Research, vol. 133, no. 1, pp. 27–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. R. J. Horvath, N. Nutile-McMenemy, M. S. Alkaitis, and J. A. Deleo, “Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures,” Journal of Neurochemistry, vol. 107, no. 2, pp. 557–569, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. H. Youn, M. S. Kwak, J. Wu et al., “Identification of lipopolysaccharide-binding peptide regions within HMGB1 and their effects on subclinical endotoxemia in a mouse model,” European Journal of Immunology, vol. 41, no. 9, pp. 2753–2762, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Anoopkumar-Dukie, J. B. Carey, T. Conere, E. O’sullivan, F. N. van Pelt, and A. Allshire, “Resazurin assay of radiation response in cultured cells,” The British Journal of Radiology, vol. 78, no. 934, pp. 945–947, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Anoopkumar-Dukie, T. Conere, J. B. Carey, and A. Allshire, “Radical mediators and mitogen-activated protein kinase signaling in oxygen-dependent radiosensitivity of human tumor cell lines,” Free Radical Biology and Medicine, vol. 39, no. 2, pp. 188–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Klegeris and P. L. McGeer, “Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP,” Journal of Leukocyte Biology, vol. 73, no. 3, pp. 369–378, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. R. K. Giri, S. K. Selvaraj, and V. K. Kalra, “Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA,” The Journal of Immunology, vol. 170, no. 10, pp. 5281–5294, 2003. View at Publisher · View at Google Scholar
  46. S. L. Yates, L. H. Burgess, J. Kocsis-Angle et al., “Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia,” Journal of Neurochemistry, vol. 74, no. 3, pp. 1017–1025, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. O. A. Olajide, H. S. Bhatia, A. C. de Oliveira, C. W. Wright, and B. L. Fiebich, “Inhibition of neuroinflammation in LPS-activated microglia by cryptolepine,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 459723, p. 10, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Gresa-Arribas, C. Viéitez, G. Dentesano, J. Serratosa, J. Saura, and C. Solà, “Modelling neuroinflammation in vitro: a tool to test the potential neuroprotective effect of anti-inflammatory agents,” PloS One, vol. 7, p. 9, article e45227, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. G. N. Levine, E. R. Bates, J. C. Blankenship et al., “2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention,” Circulation, vol. 124, no. 23, pp. 2574–2609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, P. T. O’Gara et al., “2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 61, no. 4, pp. e78–e140, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Vale, A. J. Nordmann, G. G. Schwartz et al., “Statins for acute coronary syndrome,” Cochrane Database of Systematic Reviews, vol. 9, no. 6, article Cd006870, 2011. View at Publisher · View at Google Scholar
  52. N. J. Stone, J. Robinson, A. H. Lichtenstein et al., “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology , vol. 63, no. 25, pp. 2889–2934, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. T. C. Frank-Cannon, L. T. Alto, M. A. FE, and M. G. Tansey, “Does neuroinflammation fan the flame in neurodegenerative diseases?” Molecular Neurodegeneration, vol. 4, no. 1, p. 47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. S. T. Dheen, C. Kaur, and E. A. Ling, “Microglial activation and its implications in the brain diseases,” Current Medicinal Chemistry, vol. 14, no. 11, pp. 1189–1197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Ellwardt and F. Zipp, “Molecular mechanisms linking neuroinflammation and neurodegeneration in MS,” Experimental Neurology, vol. 262, Part A, pp. 8–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Ye, Y. Huang, L. Zhao et al., “IL-1β and TNF-α induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase,” Journal of Neurochemistry, vol. 125, no. 6, pp. 897–908, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. S. M. Allan, P. J. Tyrrell, and N. J. Rothwell, “Interleukin-1 and neuronal injury,” Nature Reviews. Immunology, vol. 5, no. 8, pp. 629–640, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. W.-Y. Wang, M. S. Tan, J. T. Yu, and L. Tan, “Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease,” Annals of Translational Medicine, vol. 3, no. 10, p. 136, 2015. View at Publisher · View at Google Scholar
  59. A. Basu, J. K. Krady, and S. W. Levison, “Interleukin-1: a master regulator of neuroinflammation,” Journal of Neuroscience Research, vol. 78, no. 2, pp. 151–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. J. V. Welser-Alves and R. Milner, “Microglia are the major source of TNF-α and TGF-β1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin,” Neurochemistry International, vol. 63, no. 1, pp. 47–53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. U. K. Hanisch, “Microglia as a source and target of cytokines,” Glia, vol. 40, no. 2, pp. 140–155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Esaki, Y. Li, D. Sakata et al., “Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis,” Proceedings of the National Academy of Sciences, vol. 107, no. 27, pp. 12233–12238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Shi, J. Johansson, N. S. Woodling, Q. Wang, T. J. Montine, and K. Andreasson, “The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity,” Journal of Immunology, vol. 184, no. 12, pp. 7207–7218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Brenneis, O. Coste, K. Altenrath et al., “Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation,” The Journal of Biological Chemistry, vol. 286, no. 3, pp. 2331–2342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. T. J. Montine, D. Milatovic, R. C. Gupta, T. Valyi-Nagy, J. D. Morrow, and R. M. Breyer, “Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent,” Journal of Neurochemistry, vol. 83, no. 2, pp. 463–470, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Noda, Y. Kariura, U. Pannasch et al., “Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia,” Journal of Neurochemistry, vol. 101, no. 2, pp. 397–410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Zhao, S. G. Waxman, and B. C. Hains, “Extracellular signal-regulated kinase-regulated microglia-neuron signaling by prostaglandin E2 contributes to pain after spinal cord injury,” The Journal of Neuroscience, vol. 27, no. 9, pp. 2357–2368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Reinold, S. Ahmadi, U. B. Depner et al., “Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype,” The Journal of Clinical Investigation, vol. 115, no. 3, pp. 673–679, 2005. View at Publisher · View at Google Scholar
  69. O. Dolkart, T. Liron, O. Chechik et al., “Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study,” The American Journal of Sports Medicine, vol. 42, no. 12, pp. 2869–2876, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Björkhem-Bergman, J. D. Lindh, and P. Bergman, “What is a relevant statin concentration in cell experiments claiming pleiotropic effects?” British Journal of Clinical Pharmacology, vol. 72, no. 1, pp. 164–165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. R. von Bernhardi and J. Eugenín, “Alzheimer’s disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms,” Antioxidants & Redox Signaling, vol. 16, no. 9, pp. 974–1031, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. W. Dröge, “Free radicals in the physiological control of cell function,” Physiological Reviews, vol. 82, no. 1, pp. 47–95, 2002. View at Publisher · View at Google Scholar
  73. B. Halliwell, “Oxidative stress and neurodegeneration: where are we now?” Journal of Neurochemistry, vol. 97, no. 6, pp. 1634–1658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Valko, D. Leibfritz, J. Moncol, M. T. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” The International Journal of Biochemistry & Cell Biology, vol. 39, no. 1, pp. 44–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Asahi, Z. Huang, S. Thomas et al., “Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 6, pp. 722–729, 2005. View at Publisher · View at Google Scholar · View at Scopus